PTO/SB/26 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE or the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

Docket Number (Optional)

	REJECTION OVER A PRIOR PATENT	NY-LUD 5253.5-DIV	
	In re Application of: Thierry BOON-FALLEUR et al.		
	Application No.: 08/819,669		
	Filed: March 17, 1997		
	TUMOR REJECTION, ANTIGEN PRECURSORS, TUMOR REJECTION ANTIGENS AND USES THEREOF		
	The owner*, Ludwig Institute of Cancer Research	o f 100 percent interest in	
	the instant application hereby disclaims, except as provided below, the terminal part of the	ne statutory term of any patent granted	
	on the instant application, which would extend beyond the expiration date of the full state 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,025,	·	
·	that any patent so granted on the instant application shall be enforceable only for and or patent are commonly owned. This agreement runs with any patent granted on the instagrantee, its successors or assigns.	during such period that it and the prior	
	In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is the unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior the expiration of its full statutory term as presently shortened by any terminal disclaimer.		
	Check either box 1 or 2 below, if appropriate.		
	1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on informal and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Co and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
	2. The undersigned is an attorney or agent of record.	6/1/24	
	Signature C	Date	
06/04/2004 MA	HMED1 00000098 08819669 Norman I) Hanson	
01 FC:1814	FC:1814 110.00 0P Norman D. Hanson Typed or printed name		
	(212) 3	18-3168 e Number	
	x Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	e assignee (owner).	